OMNIAB INC (OABI)
Health Care · Antibody discovery and platform licensing · NASDAQ
OmniAb licenses proprietary engineered transgenic animals and AI-powered platforms that enable drug companies to rapidly discover next-generation therapeutic antibodies.
What OMNIAB INC does
OmniAb licenses proprietary antibody discovery technology platforms to pharmaceutical, biotech, and academic customers. The company's core offering comprises engineered transgenic animals (OmniRat, OmniChicken, OmniMouse, OmniTaur, among others) that generate diverse human antibody repertoires, combined with AI/ML tools (OmniDeep) and high-throughput screening methods. Revenue is derived through platform license agreements featuring upfront fees, annual access fees, service revenue, milestone payments, and royalties on approved products.
Themes: ["antibody discovery and therapeutic development","bispecific and multispecific biologics","antibody-drug conjugates","CAR-T cell therapies","AI/ML for drug discovery optimization","single-domain antibodies and alternative antibody modalities","platform licensing and discovery partnerships"]
Fundamentals
- Price$2.24 as of 2026-07-09 close
- Market cap$325M as of 2026-07-10
- 1-year return+11.1% as of 2026-07-09 close
- Net margin-187.6% as of 2026-07-10
- Gross margin+98.9% as of 2026-07-10
- ROE-20.3% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)+8.2% as of 2026-07-10
- Revenue CAGR (3y)-31.9% SEC XBRL
- Beta0.44 as of 2026-07-10
Dividend: 1-year non-decreasing per-share dividend streak (SEC XBRL).
Key risks (from latest filing)
["Platform license model is highly dependent on pharma/biotech partner success; if partners fail in clinical development or commercialization, milestone and royalty revenue will not materialize","Substantial unprofitability (-187.59% net margin) with accumulated deficit of $173.9M requires sustained capital to fund R&D and operations until platform monetization accelerates","Healthcare reform (IRA) and regulatory pricing pressures may limit partners' profitability and willingness to pay for discovery services, affecting licensing fees and milestone potential"]
Competitors & peers
- Genentech (Roche)
- Regeneron Pharmaceuticals
- MorphoSys (a Roche company)
- Abgenix (now part of Amgen)
- Symphogen (a Sanofi company)
- Adimab
- Integrated BioPharma
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.